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Perineural vs intravenous administration of
dexamethasone: more data are available
Editor—We read with great interest the recent editorial
wherein Martinez and Fletcher1 discussed the analgesic
effects of i.v. and perineural administration of dexamethasone,
afterpublication of asingle recent trial.2 After performing a sys-
tematic search in the PUBMED, CENTRAL, Embase, and Google
ScholarTM databases without language restriction, we were
able to capture two additional trials that specifically investi-
gated this question.3 4 Contrary to the paper by Desmet and
colleagues,2 these investigations provide support in favour of
the perineural route of administration.
Kawanishi and colleagues3 injected dexamethasone 4 mg
during nerve stimulator-guided interscalene brachial plexus
block with 20 ml of ropivacaine 0.75%, while Rahangdale and
colleagues4 used a dose of 8 mg, combined with a 0.45 ml kg21
mixture of bupivacaine 0.5% and epinephrine 1:300 000 for
ultrasound-guided sciatic nerve block. A meta-analysis on
the duration of analgesia performed with Review Manager
(RevMan version 5.2; Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration 2012) suggests that,
when compared with the i.v. route, the perineural administra-
tion of dexamethasone extends duration of analgesia by mean
differences (95% confidence interval) of 174 (278; 71) min
(P¼0.001) and 162 (324; 21) min (P¼0.05) after a fixed- and
random-effect model, respectively. Although a definitive con-
clusion cannot be drawn from a small meta-analysis of only
173 patients, and confirmation by additional randomized con-
trolled trials is warranted, the preliminary data to date favour
the perineural route.
Importantly, as Martinez and Fletcher point out, safety data
supporting perineural dexamethasone are scarce. In addition
to the clinical investigation of 60 patients5 and a subgroup ana-
lysis on 407 patients6 described by Martinez and Fletcher, we
draw attention to a series of 2000 intrathecal injections of
8 mg dexamethasone for the treatment of post-traumatic
visual disturbance in 200 patients, performed without any
neurological sequelae reported.7
In conclusion, we thank Martinez and Fletcher for their in-
sightful editorial. Although support for the clinical benefit
of perineural dexamethasone exists, we emphasize their con-
clusion that further clinical investigations should be conducted
to confirm these findings and the safety profile of this route of
administration. Only then can the widespread use of perineural
dexamethasone be recommended.
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Gastrointestinal morbidity as primary
outcomemeasure in studies comparing
crystalloid and colloid within a
goal-directed therapy
Editor—We read with interest the article by Yates and collea-
gues1 who compared a balanced crystalloid (CRY) and
balanced hydroxyethyl starch (HES) solution within a haemo-
dynamic algorithm guided by pulse power wave analysis in
patients undergoing elective colorectal surgery. The primary
outcome measure was the inability to tolerate a full enteral
diet at postoperative day 5 (POD5) either by mouth or via a
feeding tube for any reason, including nausea, vomiting, ab-
dominal distension, or ileus.1 While their results showed no dif-
ference between the HES and CRYgroups, a total of 31% of the
study patients failed to tolerate a full diet on POD5. This result is
seriously contrasting with a recently published study by Feld-
heiser and colleagues,2 also comparing a balanced crystalloid
and a balanced colloid solution within a goal-directed haemo-
dynamic algorithm in patients with metastatic ovarian carcin-
oma undergoing cytoreductive surgery. They reported a lower
rate of 18.7% not tolerating a full diet on POD5, despite a sub-
stantially higher POSSUM operative score (32 vs 12 points).
Postoperative gastrointestinal (GI) morbidity as primary
outcome measure in studies comparing two i.v. solutions
seems to be very challenging as this primary endpoint is
assumed to be multifactorial and can only be compared appro-
priately if multiple factors contributing to postoperative ileus
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